Zi Yun Ng
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma
Ng, Zi Yun; Bishton, Mark; Ritchie, David; Campbell, Robert; Gilbertson, Michael; Hill, Kate; Ratnasingam, Sumita; Schwarer, Anthony; Manos, Kate; Shorten, Sophie; Ng, Melissa; Nelson, Niles; Xin, Liu; De Mel Widanalage, Sanjay; Sunny, Tenny; Purtill, Duncan; Poon, Michelle; Johnston, Anna; Cochrane, Tara; Lee, Hui‐Peng; Hapgood, Greg; Tam, Constantine; Opat, Stephen; Hawkes, Eliza; Seymour, John; Cheah, Chan Yoon
Authors
Mark Bishton
David Ritchie
Robert Campbell
Michael Gilbertson
Kate Hill
Sumita Ratnasingam
Anthony Schwarer
Kate Manos
Sophie Shorten
Melissa Ng
Niles Nelson
Liu Xin
Sanjay De Mel Widanalage
Tenny Sunny
Duncan Purtill
Michelle Poon
Anna Johnston
Tara Cochrane
Hui‐Peng Lee
Greg Hapgood
Constantine Tam
Stephen Opat
Eliza Hawkes
John Seymour
Chan Yoon Cheah
Abstract
Mantle cell lymphoma (MCL) is an uncommon and typically aggressive form of lymphoma. Although often initially chemosensitive, relapse is common. Several induction and conditioning regimens are used in transplant-eligible patients, and the optimal approach remains unknown. We performed an international, retrospective study of transplant-eligible patients to assess impact of induction chemoimmunotherapy and conditioning regimens on clinical outcomes. We identified 228 patients meeting inclusion criteria. Baseline characteristics were similar among the induction groups except for some variation in age. The type of induction chemoimmunotherapy received did not influence overall response rates (ORRs) (0.43), progression-free survival (PFS) (P > .67), or overall survival (OS) (P > .35) on multivariate analysis (PFS and OS). Delivery of autologous stem cell transplant (ASCT) was associated with favorable PFS and OS (0.01) on univariate analysis only; this benefit was not seen on multivariate analysis—PFS (0.36) and OS (0.21). Compared with busulfan and melphalan (BuMel), the use of the carmustine, etoposide, cytarabine, melphalan (BEAM)–conditioning regimen was associated with inferior PFS (HR = 2.0 [95% CI 1.1-3.6], 0.02) but not OS (HR = 1.1 [95% CI 0.5-2.3], 0.81) on univariate analysis only. Within the limits of a retrospective study and modest power for some comparisons, type of induction therapy did not influence ORR, PFS, or OS for transplant-eligible patients with MCL. International efforts are required to perform randomized clinical trials evaluating chemoimmunotherapy induction regimens.
Citation
Ng, Z. Y., Bishton, M., Ritchie, D., Campbell, R., Gilbertson, M., Hill, K., …Cheah, C. Y. (2019). A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. Hematological Oncology, 37(3), 253-260. https://doi.org/10.1002/hon.2618
Journal Article Type | Article |
---|---|
Acceptance Date | Apr 11, 2019 |
Online Publication Date | May 24, 2019 |
Publication Date | 2019-08 |
Deposit Date | Aug 1, 2023 |
Journal | Hematological Oncology |
Print ISSN | 0278-0232 |
Electronic ISSN | 1099-1069 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 37 |
Issue | 3 |
Pages | 253-260 |
DOI | https://doi.org/10.1002/hon.2618 |
Keywords | Cancer Research; Oncology; Hematology; General Medicine |
Public URL | https://nottingham-repository.worktribe.com/output/23550546 |
PMID | 30983008 |
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: digital-library-support@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search